S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
The single greatest medical breakthrough of all time? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
The single greatest medical breakthrough of all time? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
The single greatest medical breakthrough of all time? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
The single greatest medical breakthrough of all time? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
The single greatest medical breakthrough of all time? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
The single greatest medical breakthrough of all time? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
The single greatest medical breakthrough of all time? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
The single greatest medical breakthrough of all time? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:CSTL

Castle Biosciences (CSTL) Stock Forecast, Price & News

$16.52
-0.14 (-0.84%)
(As of 09/22/2023 ET)
Compare
Today's Range
$16.37
$16.72
50-Day Range
$15.30
$19.93
52-Week Range
$9.26
$30.08
Volume
102,471 shs
Average Volume
181,459 shs
Market Capitalization
$442.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.29

Castle Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
95.4% Upside
$32.29 Price Target
Short Interest
Healthy
2.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.15mentions of Castle Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.37 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.68) to ($3.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

271st out of 966 stocks

Medical Laboratories Industry

7th out of 23 stocks


CSTL stock logo

About Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CSTL Price History

CSTL Stock News Headlines

Castle Scales Higher on Industry Award
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Castle Biosciences (NASDAQ: CSTL)
Castle Biosciences Reports Second Quarter 2023 Results
Why Castle Biosciences Stock Is Jumping Today
Castle Biosciences's Earnings: A Preview
BTIG Remains a Buy on Castle Biosciences (CSTL)
Why Shares of Castle Biosciences Fell This Week
BTIG Sticks to Its Buy Rating for Castle Biosciences (CSTL)
See More Headlines
Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CSTL Company Calendar

Last Earnings
8/02/2023
Today
9/22/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CSTL
Fax
N/A
Employees
582
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.29
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+95.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-67,140,000.00
Pretax Margin
-52.98%

Debt

Sales & Book Value

Annual Sales
$137.04 million
Book Value
$15.15 per share

Miscellaneous

Free Float
24,746,000
Market Cap
$442.90 million
Optionable
Not Optionable
Beta
0.81
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Derek J. MaetzoldMr. Derek J. Maetzold (Age 61)
    Founder, CEO, Pres & Director
    Comp: $1.45M
  • Mr. Frank StokesMr. Frank Stokes (Age 53)
    CFO & Treasurer
    Comp: $849.36k
  • Ms. Kristen M. Oelschlager R.N.Ms. Kristen M. Oelschlager R.N. (Age 55)
    RN, Chief Operating Officer
    Comp: $782.7k
  • Mr. Tobin W. Juvenal (Age 63)
    Chief Commercial Officer
    Comp: $782.7k
  • Camilla Zuckero
    VP of Investor Relations & Corp. Affairs
  • Ms. Alice Bahner Izzo
    Sr. VP of Marketing
  • Ms. Keli Greenberg
    VP of HR & Exec. Director of HR
  • Dr. Robert W. Cook Ph.D. (Age 51)
    Sr. VP of R&D
  • Mr. Bernhard E. SpiessMr. Bernhard E. Spiess (Age 63)
    Company Sec.













CSTL Stock - Frequently Asked Questions

Should I buy or sell Castle Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings
or view top-rated stocks.

What is Castle Biosciences' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price targets for Castle Biosciences' stock. Their CSTL share price forecasts range from $25.00 to $41.00. On average, they anticipate the company's share price to reach $32.29 in the next twelve months. This suggests a possible upside of 95.4% from the stock's current price.
View analysts price targets for CSTL
or view top-rated stocks among Wall Street analysts.

How have CSTL shares performed in 2023?

Castle Biosciences' stock was trading at $23.54 on January 1st, 2023. Since then, CSTL shares have decreased by 29.8% and is now trading at $16.52.
View the best growth stocks for 2023 here
.

When is Castle Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our CSTL earnings forecast
.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.31. The firm had revenue of $50.14 million for the quarter, compared to analysts' expectations of $43.51 million. Castle Biosciences had a negative net margin of 53.04% and a negative trailing twelve-month return on equity of 22.57%.

What ETF holds Castle Biosciences' stock ?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

When did Castle Biosciences IPO?

(CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Castle Biosciences' stock symbol?

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (11.51%), Granahan Investment Management LLC (9.43%), BlackRock Inc. (7.95%), Principal Financial Group Inc. (5.07%), Bellevue Group AG (4.19%) and Palisade Capital Management LP (2.25%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends
.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Castle Biosciences' stock price today?

One share of CSTL stock can currently be purchased for approximately $16.52.

How much money does Castle Biosciences make?

Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $442.90 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

How many employees does Castle Biosciences have?

The company employs 582 workers across the globe.

How can I contact Castle Biosciences?

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com.

This page (NASDAQ:CSTL) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -